INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations Meeting Abstract
| Authors: | Zalcberg, J. R.; Blay, J. Y.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Reichmann, W.; Sprott, K.; Cox, P.; Sherman, M. L.; Ruiz-Soto, R.; Heinrich, M. C.; Bauer, S.; George, S.; on behalf of the INSIGHT study investigators |
| Abstract Title: | INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations |
| Meeting Title: | 2024 ASCO Gastrointestinal Cancers Symposium |
| Keywords: | 298-145-222-184-1022-9126; 281-206-4760-6705; 281-318-9082; 38092-25152; 283-237-2401; 3282-206-4761-4968; 130-540-543-12277; 38092-25699 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2024 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-01-20 |
| Language: | English |
| ACCESSION: | WOS:001266680500639 |
| DOI: | 10.1200/JCO.2024.42.3_suppl.TPS767 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS767 -- Source: Wos |
